What is Opus Genetics, Inc. (IRD) stock price today?

Opus Genetics, Inc. (IRD) currently trades at $4.99 per share. The stock has a market capitalization of $356.30M and a P/E ratio of —x.

Is IRD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Opus Genetics, Inc. has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -7.40.

What is Opus Genetics, Inc.'s revenue and earnings?

Opus Genetics, Inc. has trailing twelve-month (TTM) revenue of $14.20M with profit margins of 0.00%. Earnings per share (EPS) is $-0.80.

Is Opus Genetics, Inc. financially healthy?

Opus Genetics, Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -7.40 places it in the distress.

IRD

Opus Genetics, Inc.

NASDAQ: IRD · HEALTHCARE · BIOTECHNOLOGY

$4.99

-6.90% today

Updated 2026-05-08

Market cap

$356.30M

P/E ratio

—

P/S ratio

25.10x

EPS (TTM)

$-0.80

Dividend yield

—

52W range

$1 – $6

Volume

0.9M

Market cap

$356.30M

P/E ratio

—

P/S ratio

25.10x

EPS (TTM)

$-0.80

Dividend yield

—

52W range

$1 – $6

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-7.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →194 stocks currently score above 75

Price targets

Analyst target

$10.20

+104.41%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.18x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -7.40 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-9.83M

- Revenue declining -10.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$39.85M	$19.05M	$10.99M	$14.20M	$14.20M
Net income	$17.89M	$-9.99M	$-57.53M	$-49.59M	$-16.52M
EPS	—	—	—	—	$-0.80
Free cash flow	$14.31M	$-1.11M	$-25.58M	$-35.25M	$-9.83M
Profit margin	44.89%	-52.42%	-523.40%	-349.33%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IRD	$356.30M	17	2.7	2.5	5.0	5.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Opus Genetics, Inc. trades at $4.99. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -7.40, it sits in the distress. TTM revenue stands at $14.20M.

Frequently asked questions

What is Opus Genetics, Inc.'s stock price?

Opus Genetics, Inc. (IRD) trades at $4.99.

Is Opus Genetics, Inc. overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell).

What is the price target of Opus Genetics, Inc. (IRD)?

The analyst target price is $10.20, representing +104.4% upside from the current price of $4.99.

What is Opus Genetics, Inc.'s revenue?

TTM revenue is $14.20M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-7.40 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

opusgtx.com

Quick metrics

P/S ratio25.10x

ROE-242.40%

Beta0.63

50D MA$4.95

200D MA$2.72

Shares out0.07B

Float0.03B

Short ratio—

Avg volume0.9M

Performance

1 week-9.04%

1 month+20.23%

3 months+104.30%

YTD+160.20%

1 year—

3 years—

5 years—

Compare

IRD vs LLY →IRD vs JNJ →IRD vs ABBV →Stock screener →